[Clinical trial of drugs for treating urological infections--pipemidic acid].
A method was elaborated for clinical trial of pharmaceuticals for the treatment of infections of kidneys and urinary ducts. The main requirements are as follows: definitive diagnostic criteria for urological infection, monotherapy, systematic control for the drug intake, precisely formulated indices for assessment of the effect, strict follow-up of adverse and toxic effects. The effect was assessed according to a three-stage scale: very good, good and poor, consideration given not only to the clinical and laboratory indices but to adverse effects as well. Pipemidic acid was studied according to that model--the acid being a new chemotherapeutic, similar to nalidixic acid according to chemical composition and action. Out of all 29 patients treated, 19 were with very good effect, with good--6, and with poor--4. The adverse effects were negligible--one patient had light urticarial rash and pruritus.